Supriya Lifescience Limited (NSE:SUPRIYA)
India · Delayed Price · Currency is INR 644.45
+6.55 (1.03%)
Nov 12, 2026, 3:29 PM IST
Supriya Lifescience Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 8,790 | 8,279 | 6,965 | 5,703 | 4,609 | 5,300 |
Other Revenue | -4.59 | - | - | - | - | - |
| 8,786 | 8,279 | 6,965 | 5,703 | 4,609 | 5,300 | |
Revenue Growth | 22.93% | 18.87% | 22.12% | 23.73% | -13.04% | 35.49% |
Cost of Revenue | 3,293 | 2,894 | 2,343 | 2,322 | 1,961 | 2,035 |
Gross Profit | 5,492 | 5,385 | 4,622 | 3,381 | 2,649 | 3,266 |
Selling, General & Admin | 1,098 | 1,023 | 859.5 | 724.21 | 730.21 | 655.81 |
Other Operating Expenses | 1,765 | 1,412 | 1,153 | 896.37 | 628.48 | 465.44 |
Operating Expenses | 3,200 | 2,720 | 2,217 | 1,779 | 1,477 | 1,222 |
Operating Income | 2,293 | 2,665 | 2,405 | 1,602 | 1,172 | 2,043 |
Interest Expense | -26.76 | -27.72 | -18.1 | -51.49 | -30.84 | -41.98 |
Interest & Investment Income | 60.32 | 60.32 | 40.19 | 83.57 | 95.16 | 70.94 |
Other Non Operating Income (Expenses) | 0.08 | 0.08 | -0.01 | 0.02 | -0.02 | 0.1 |
EBT Excluding Unusual Items | 2,326 | 2,698 | 2,427 | 1,635 | 1,236 | 2,072 |
Gain (Loss) on Sale of Investments | 53.36 | 53.36 | 55.65 | 22.4 | - | - |
Gain (Loss) on Sale of Assets | -0.09 | -0.09 | -0.06 | - | -1.11 | - |
Other Unusual Items | -4.58 | -4.58 | - | - | - | - |
Pretax Income | 2,376 | 2,748 | 2,485 | 1,657 | 1,235 | 2,072 |
Income Tax Expense | 604.23 | 656.59 | 605.23 | 465.76 | 336.3 | 554.35 |
Net Income | 1,772 | 2,091 | 1,880 | 1,191 | 898.57 | 1,518 |
Net Income to Common | 1,772 | 2,091 | 1,880 | 1,191 | 898.57 | 1,518 |
Net Income Growth | -2.84% | 11.26% | 57.80% | 32.56% | -40.81% | 22.83% |
Shares Outstanding (Basic) | 80 | 80 | 80 | 80 | 80 | 80 |
Shares Outstanding (Diluted) | 80 | 80 | 80 | 80 | 80 | 80 |
Shares Change | 0.17% | - | - | - | - | 9.97% |
EPS (Basic) | 22.01 | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 |
EPS (Diluted) | 22.01 | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 |
EPS Growth | -3.00% | 11.26% | 57.77% | 32.62% | -40.83% | 11.68% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 456.68 | 335.34 | 22.99 | -323.48 | -443.05 | -111.03 |
Free Cash Flow Per Share | 5.67 | 4.17 | 0.29 | -4.02 | -5.50 | -1.38 |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 0.800 | 0.600 | 0.600 |
Dividend Growth | - | 0% | 25.00% | 33.33% | 0% | 11.11% |
Gross Margin | 62.52% | 65.05% | 66.36% | 59.28% | 57.46% | 61.61% |
Operating Margin | 26.10% | 32.20% | 34.53% | 28.10% | 25.42% | 38.55% |
Profit Margin | 20.17% | 25.26% | 26.99% | 20.89% | 19.49% | 28.64% |
Free Cash Flow Margin | 5.20% | 4.05% | 0.33% | -5.67% | -9.61% | -2.10% |
EBITDA | 2,622 | 2,941 | 2,601 | 1,752 | 1,281 | 2,136 |
EBITDA Margin | 29.84% | 35.53% | 37.34% | 30.72% | 27.80% | 40.31% |
D&A For EBITDA | 329.15 | 276.06 | 196.15 | 149.62 | 109.7 | 93.01 |
EBIT | 2,293 | 2,665 | 2,405 | 1,602 | 1,172 | 2,043 |
EBIT Margin | 26.10% | 32.19% | 34.53% | 28.10% | 25.42% | 38.55% |
Effective Tax Rate | 25.43% | 23.89% | 24.36% | 28.11% | 27.23% | 26.75% |
Revenue as Reported | 8,900 | 8,394 | 7,063 | 5,810 | 4,704 | 5,376 |
Advertising Expenses | - | 56.18 | 53.82 | 47.34 | 173.92 | 165.03 |